Home / Expertise / Life Sciences & Healthcare
volvox colony bright field microscope magnification 40x

Life Sciences & Healthcare

International

With more than 300 lawyers, patent attorneys, scientists and academics’ across CMS and the support of the Life Sciences Asia-Pacific Network (LAN), we understand the scientific and commercial as well as the legal imperatives affecting your life sciences & healthcare business. We work with and have established long-term relationships with the top 100 life sciences & healthcare companies in the areas of pharmaceuticals, medical devices, biotechnology, agriculture and food, including the top 20 global pharmaceutical companies and nine out of the top ten global medical device companies.

Our experts, many of whom have worked in-house in your sector, have developed a shared capability in the areas of pharmaceuticals, biotechnology, medical devices and diagnostics. With active memberships in major industry associations such as the ABPI, ABHI, BIVDA, PAGB, EUCOMED and EFPIA, we help shape the legal frameworks impacting the life sciences & healthcare sector. We regularly advise our clients on their day-to-day operational needs such as support with advertisement and promotion of medicine, public sector procurement, pricing and reimbursement, patent enforcement, commercial and clinical trial agreements as well as regulatory advice. Equally, when you need life sciences & healthcare specialist advice for strategic agreements, planning a corporate transaction or embarking on litigation (whether product liability or otherwise), we have a team that is well versed in the industry issues to help you.

Read more Read less
May 2020
CMS Life Sci­ences & Health­care Glob­al Bro­chure
With more than 300 law­yers, pat­ent at­tor­neys, sci­ent­ists and aca­dem­ics’ across CMS and the sup­port of the Life Sci­ences Asia-Pa­cific Net­work (LAN), we un­der­stand the sci­entif­ic and com­mer­cial as well as the leg­al im­per­at­ives af­fect­ing your life sci­ences & health­care busi­ness. We work with and have es­tab­lished long-term re­la­tion­ships with the top 100 life sci­ences & health­care com­pan­ies in the areas of phar­ma­ceut­ic­als, med­ic­al devices, bi­o­tech­no­logy, ag­ri­cul­ture and food, in­clud­ing the top 20 glob­al phar­ma­ceut­ic­al com­pan­ies and nine out of the top ten glob­al med­ic­al device com­pan­ies. Our ex­perts, many of whom have worked in-house in your sec­tor, have de­veloped a shared cap­ab­il­ity in the areas of phar­ma­ceut­ic­als, bi­o­tech­no­logy, med­ic­al devices and dia­gnostics. With act­ive mem­ber­ships in ma­jor in­dustry as­so­ci­ations such as the ABPI, ABHI, BIVDA, PAGB, EUCOMED and EFPIA, we help shape the leg­al frame­works im­pact­ing the life sci­ences & health­care sec­tor. We reg­u­larly ad­vise our cli­ents on their day-to-day op­er­a­tion­al needs such as sup­port with ad­vert­ise­ment and pro­mo­tion of medi­cine, pub­lic sec­tor pro­cure­ment, pri­cing and re­im­burse­ment, pat­ent en­force­ment, com­mer­cial and clin­ic­al tri­al agree­ments as well as reg­u­lat­ory ad­vice. Equally, when you need life sci­ences & health­care spe­cial­ist ad­vice for stra­tegic agree­ments, plan­ning a cor­por­ate trans­ac­tion or em­bark­ing on lit­ig­a­tion (wheth­er product li­ab­il­ity or oth­er­wise), we have a team that is well versed in the in­dustry is­sues to help you. 
Brochure
Dec 2018
CMS Life Sci­ences & Health­care Sec­tor Group: An over­view of our Asia-Pa­cific,...
CMS has a truly glob­al Life Sci­ences & Health­care Sec­tor Group with over 300 law­yers and pat­ent at­tor­neys fo­cused on the sec­tor. Out­side of Europe, we are rap­idly grow­ing as a group and have teams in Lat­in Amer­ica, Middle East and North Africa and Asia-Pa­cific to sup­port you and your busi­ness wherever you are.560340ht­tps://me­dia.cmsleg­al.com/me­dia/em­bed?key=ec0e940ec0e4046266a871c8a2f32b9d&unique_key=8bcabe979b2f0ed4df8ed96fe4ad25d1&width=720&height=405&auto­play=false&auto­light­soff=false&loop=false&clean1al­wayseznode://499627
Brochure
On the Pulse
Wel­come to ‘On the Pulse’ de­livered by the Glob­al Life Sci­ences & Health­care Sec­tor GroupA video/pod­cast series, On the Pulse, brings to­geth­er CMS law­yers and ex­perts to dis­cuss key in­dustry top­ics im­pact­ing, in­nov­at­ing and dis­rupt­ing the life sci­ences & health­care sec­tor. The series is hos­ted by Nick Beck­ett, Glob­al Co-Head of CMS Life Sci­ences & Health­care Sec­tor Group.Sub­scribe, down­load, watch and listen to the CMS ‘On the Pulse’ videos here and pod­casts here. VideoNew! Epis­ode #4 – Di­git­al Health – Part 2In this fi­nal epis­ode (Part 2), we dis­cuss:an in­creas­ing de­mand for di­git­al health and in­crease in tele-con­sulta­tions and use of chat­botsthe di­git­al­isa­tion of health­care re­cordsthe ap­proach of Big Tech and their pro­vi­sion of ad­vanced tech­nic­al solu­tionsdata pri­vacy re­quire­ments re­gard­ing the use of im­mense data re­serves in the pro­vi­sion of di­git­al health ser­vicesthe need to in­cor­por­ate hu­man in­sight and over­sight in­to AI sys­tem pro­cesses 340560eznode://586467truetruefalseEpis­ode #3 - Di­git­al Health – Part 1Nick Beck­ett dis­cusses di­git­al health with Rob Flaws (CMS Dubai), Ni­all Mc­Al­ister (CMS UK) and Ro­land Wir­ing (CMS Ger­many).In this epis­ode (Part 1), we dis­cuss:the need for col­lab­or­a­tions and to deal with a po­ten­tial clash of cul­tures in bring­ing the “di­git­al” and “health” sides of the in­dustry to­geth­erthe use of AI in track-and-trace and the search for a vac­cine for COV­ID-19the lack of clar­ity of the defin­i­tion of AIwheth­er the EC White Pa­per suf­fi­ciently provides a com­pre­hens­ive pro­pos­al for reg­u­la­tion of AI, and wheth­er new le­gis­la­tion is re­quiredwhere li­ab­il­ity rests in re­spect of soft­ware 340560ht­tps://me­dia.cmsleg­al.com/me­dia/em­bed?key=89a1b41f0289fded­dc2d139a846e0daf&unique_key=72b6864e91ef1c7f765cd0777aa960a5&width=720&height=405&auto­play=false&auto­light­soff=false&loop=false&cleantruetruetrueeznode://583572Epis­ode #2 - Ad­vert­ising of medi­cines and med­ic­al devicesNick Beck­ett dis­cusses with Dora Petra­nyi (CMS Hun­gary), Jens Wag­n­er (CMS Ger­many) and Gab­ri­ela Staber (CMS Aus­tria) the ad­vert­ising of medi­cines and med­ic­al devices provid­ing prac­tic­al in­sights and an over­view of the ap­plic­able laws.In the epis­ode, we con­sider:the com­plic­ated and fast chan­ging area of reg­u­la­tion of ad­vert­ise­ments with dif­fer­ent rules in dif­fer­ent jur­is­dic­tionshow to veri­fy that sci­entif­ic evid­ence is suf­fi­cient to sub­stan­ti­ate claimsthe use of ad­vert­ising in so­cial me­dia and oth­er pro­mo­tion­al cam­paignsthe ap­proach of the au­thor­it­ies to new entrants to the mar­ket in­clud­ing in times of crisisrisks as­so­ci­ated with com­pet­it­ors or con­sumer pro­tec­tion or­gan­isa­tions fil­ing claimsthe po­ten­tial im­pact of MDR on ad­vert­ising of med­ic­al devices 340560ht­tps://me­dia.cmsleg­al.com/me­dia/em­bed?unique_key=6f8d44dd­fb8a01d78475bb1c611c30db&width=720&height=405&auto­play=false&auto­light­soff=false&loop=false&cleantruetruetrueeznode://579988Epis­ode #1 – A leg­al roadmap for Can­nabisNick Beck­ett dis­cusses with Shuna Ma­son (CMS UK), El­len Gielen (CMS Neth­er­lands), Laura Opilio (CMS Italy) and how the medi­cin­al can­nabis in­dustry is de­vel­op­ing across Europe, the chal­lenges it faces and what the fu­ture might hold. In par­tic­u­lar, we dis­cuss in this epis­ode:po­ten­tially the largest can­nabis mar­ket on the plan­et;how Moore’s law seems to ap­ply to the leg­al open­ing up by au­thor­it­ies in Europe;why there is yet to be sig­ni­fic­ant use in prac­tice;what stud­ies are needed to provide the hard sci­entif­ic evid­ence health­care pro­fes­sion­als and au­thor­it­ies need to be com­fort­able with the ef­fic­acy and safety of medi­cin­al can­nabis;wheth­er re­cre­ation­al use in cof­fee shops may be di­ver­ted for med­ic­al use;wheth­er food sup­ple­ments, cos­met­ics, drinks or even ci­gar­ettes could be an al­tern­at­ive means for pa­tients to re­ceive can­nabis for med­ic­al pur­poses. 340560ht­tps://me­dia.cmsleg­al.com/me­dia/em­bed?unique_key=18be30a5a03cbe6d3e247b6f373f1e2c&width=720&height=405&auto­play=false&auto­light­soff=false&loop=false&cleantruetruetrueeznode://573063 Pod­castNew! Epis­ode #4 – Di­git­al Health – Part 2Epis­ode #3 - Di­git­al Health – Part 1Epis­ode #2 - Ad­vert­ising of medi­cines and med­ic­al devicesEpis­ode #1 – A leg­al roadmap for Can­nabis
Publication

Feed

Show only
31 July 2020
An­nu­al Re­view 2019 – 2020
Publication
20 April 2020
CMS Ex­pert Guide to ad­vert­ising of medi­cines and med­ic­al devices
Are you look­ing for in­form­a­tion on phar­ma­ceut­ic­al ad­vert­ising reg­u­la­tion and med­ic­al device ad­vert­ising? Learn more about it in this CMS Ex­pert Guide.
Expert Guide Life Sciences & Healthcare
08 July 2020
“WIPO PROOF”: WIPO’s new on­line ser­vice which helps in­nov­at­ors and cre­at­ors...
The World In­tel­lec­tu­al Prop­erty Or­gan­isa­tion (WIPO) re­cently launched its new on­line busi­ness ser­vice, “WIPO PROOF”. The plat­form aims to help in­nov­at­ors and cre­at­ors safe­guard their in­tel­lec­tu­al...
Law-Now Life Sciences & Healthcare
27 July 2020
On the Pulse
Wel­come to ‘On the Pulse’ de­livered by the Glob­al Life Sci­ences & Health­care Sec­tor Group
Publication Life Sciences & Healthcare
20 April 2020
CMS Ex­pert Guide to can­nabis law and le­gis­la­tion
Are you look­ing for in­form­a­tion on can­nabis law and le­gis­la­tion? This CMS Ex­pert Guide provides you with everything you need to know.
Expert Guide Life Sciences & Healthcare
26 May 2020
European Com­mis­sion must ad­dress in­tel­lec­tu­al prop­erty and AI
The Com­mit­tee on Leg­al Af­fairs (JURI) of the European Par­lia­ment has pub­lished three draft re­ports re­lat­ing to ar­ti­fi­cial in­tel­li­gence (AI). This note is about the draft re­port on in­tel­lec­tu­al prop­erty...
Law-Now Life Sciences & Healthcare
18 March 2020
#1ex­pert1minute – CMS ex­perts on the im­pact of Cov­id-19
Video series
Publication COVID-19: The new normal?
22 May 2020
For­eign in­vest­ments in Ger­man life sci­ence com­pan­ies be­come sub­ject to...
In re­sponse to the COV­ID-19 pan­dem­ic, Ger­many has widened the scope of its in­vest­ment con­trol to in­clude nu­mer­ous life sci­ence com­pan­ies. The amend­ments to the For­eign Trade and Pay­ments Or­din­ance ("AWV")...
Law-Now Life Sciences & Healthcare
26 November 2019
Fu­ture fa­cing life sci­ence and health­care: A wealth of op­por­tun­it­ies, an...
News Life Sciences & Healthcare
17 April 2020
Is a pri­vacy-friendly use of mo­bile ap­plic­a­tions to com­bat COV­ID-19 our...
A Pan-European Ap­proach to the Use of Mo­bile Apps and Mo­bile Data With its Re­com­mend­a­tion of 8 April 2020 on steps and meas­ures to de­vel­op a com­mon ap­proach to the use of mo­bile ap­plic­a­tions and mo­bile...
Law-Now COVID-19: The new normal?
May 2020
CMS Life Sci­ences & Health­care Glob­al Bro­chure
Brochure Life Sciences & Healthcare
27 March 2020
Man­aging clin­ic­al tri­als un­der COV­ID-19: New EU guid­ance is­sued for spon­sors...
The COV­ID-19 pan­dem­ic has had a dra­mat­ic im­pact on European health sys­tems, whose pri­or­ity first and fore­most is the treat­ment of pa­tients suf­fer­ing from this dis­ease both in the in-pa­tient and out-pa­tient...
Law-Now COVID-19: The new normal?
Load more articles